Sigma Of Australia Battle Over Effexor Eyed Closely By Others
This article was originally published in PharmAsia News
Australia's Sigma Pharmaceutical and its attempts to break loose of Wyeth's Effexor (venlafaxine) antidepressant are being watched closely by other generics makers as Sigma wages its patent battles. Effexor is the best-selling antidepressant in Australia and Sigma has lost its first court challenge to break the patent. Sigma faces two other patents Wyeth claims for the drug. Other generics makers seek to market the drug in Australia where the national health plan shelled out about $80.7 million for it last year. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.